ANP  Vol.2 No.1 , February 2013
Studies on Dissolution Behaviour of Nanoparticulate Curcumin Formulation
Author(s) R. Ravichandran

Curcumin is the main biologically active phytochemical compound of turmeric that has been widely used by ancient cultures throughout Asia. However the dissolution rate limited absorption and pre-absorption degradation limits its use as a potential therapeutic. In this study an attempt has been made to overcome the above limitations by curcumin delivery through nanotechnology. Nanocurcumin solid dosage formulations were prepared and studied for its dissolution behaviour. Considerable improvement in the dissolution behavior was observed in the drug nanocrystal-loaded solid dosage forms. This is expected to enhance the bioavailability of poorly soluble medicinal herbs such as turmeric in the body.

Cite this paper
Ravichandran, R. (2013) Studies on Dissolution Behaviour of Nanoparticulate Curcumin Formulation. Advances in Nanoparticles, 2, 51-59. doi: 10.4236/anp.2013.21010.
[1]   S. Shishodia, G. Sethi and B. B. Aggarwal, “Curcumin: Getting Back to the Roots,” Annals of the New York Aca demy of Sciences, Vol. 1056, No. 1, 2005, pp. 206-217. doi:10.1196/annals.1352.010

[2]   I. Chattopadhyay, K. Biswas, U. Bandyopadhyay and R. K. Banerjee, “Turmeric and Curcumin: Biological Ac tions and Medicinal Applications,” Current Science, Vol. 87, No. 1, 2004, pp. 44-50.

[3]   J. A. Duke, “CRC Handbook of Medicinal Spices,” CRC Press, New York, 2002, pp. 137-144. doi:10.1201/9781420040487

[4]   H. P. T. Ammon and M. A. Wahl, “Pharmacology of Curcumin,” Planta Medica, Vol. 57, No. 1, 1991, pp. 1-7. doi:10.1055/s-2006-960004

[5]   B. B. Aggarwal, C. Sundaram, N. Malani and H. Ichikawa, “Curcumin: The Indian Solid Gold,” Advances in Experi mental Medicine and Biology, Vol. 595, 2007, pp. 1-75. doi:10.1007/978-0-387-46401-5_1

[6]   H. Hatcher, R. Planalp, J. Cho, F. M. Torti and S. V. Torti, “Curcumin: From Ancient Medicine to Current Clinical Trials,” Cellular and Molecular Life Sciences, Vol. 65, No. 11, 2008, pp. 1631-1652. doi:10.1007/s00018-008-7452-4

[7]   B. Joe, M. Vijaykumar and B. R. Lokesh, “Biological Properties of Curcumin-Cellular and Molecular Mecha nisms of Action,” Critical Reviews in Food Science and Nutrition, Vol. 44, No. 2, 2004, pp. 97-111. doi:10.1080/10408690490424702

[8]   C. Mancuso and E. Barone, “Curcumin in Clinical Practice: Myth or Reality?” Trends in Pharmacological Sciences, Vol. 30, No. 7, 2009, pp. 333-334. doi:10.1016/

[9]   R. K. Maheshwari, A. K. Singh, J. Gaddipati and R. C. Srimal, “Multiple Biological Activities of Curcumin: A Short Review,” Life Sciences, Vol. 78, No. 18, 2006, pp. 2081-2087. doi:10.1016/j.lfs.2005.12.007

[10]   A. Duvoix, R. Blasius, S. Delhalle, M. Schnekenburger, F. Morceau, E. Henry, M. Dicato and M. Diederich, “Che mopreventive and Therapeutic Effects of Curcumin,” Cancer Letters, Vol. 223, No. 2, 2005, pp. 181-190. doi:10.1016/j.canlet.2004.09.041

[11]   US Food and Drug Administration.

[12]   H. H. Tonnesen and J. Karlsen, “Studies of Curcumin and Curcuminoids: V. Alkaline Degradation of Curcumin,” Zeitschrift für Lebensmittel-Untersuchung und Forschung, Vol. 180, No. 2, 1985, pp. 132-134.

[13]   P. Anand, A. B. Kunnumakkara, R. A. Newman and B. B. Aggarwal, “Bioavailability of Curcumin: Problems and Promises,” Molecular Pharmaceutics, Vol. 4, No. 6, 2007, pp. 807-818. doi:10.1021/mp700113r

[14]   A. K. Bansal, B. Munjal and S. Patel, “Novel Self Emul sifying Curcumin Compositions with Enhanced Bioavail ability,” PCT Filed, No. PCT/IB/2009/005154, 2009.

[15]   A. K. Bansal, B. Munjal and S. Patel, “Novel Self Nano Emulsifying Curcumin (Curcuminoids) Composition with Enhanced Bioavailability,” Indian Patent No. 1776/DEL/ 2008, 2008.

[16]   C. D. Lao, M. T. T. Ruffin, D. Normolle, D. D. Heath, S. I. Murray, J. M. Bailey, M. E. Boggs, J. Crowell, C. L. Rock and D. E. Brenner, “Dose Escalation of a Curcumi noid Formulation,” BMC Complementary and Alternative Medicine, Vol. 6, No. 1, 2006, p. 10. doi:10.1186/1472-6882-6-10

[17]   G. Shoba, D. Joy, T. Joseph, M. Majeed, R. Rajendran and P. S. Srinivas, “Influence of Piperine on the Pharma cokinetics of Curcumin in Animals and Human Volun teers,” Planta Medica, Vol. 64, No. 4, 1998, pp. 353-356. doi:10.1055/s-2006-957450

[18]   L. Li, F. S. Braiteh and R. Kurzrock, “Liposome-Encap sulated Curcumin: In Vitro and in Vivo Effects on Prolif eration, Apoptosis, Signaling, and Angiogenesis,” Cancer, Vol. 104, No. 6, 2005, pp. 1322-1331. doi:10.1002/cncr.21300

[19]   Bisht, Savita, et al., “Polymeric Nanoparticle-Encapsulated Curcumin (‘Cur-NC’): A Novel Strategy for Human Cancer Therapy,” Journal of Nanobiotechnology, Vol. 5, No. 3, 2007, p. 3. doi:10.1186/1477-3155-5-3

[20]   A. Liu, H. Lou, L. Zhao and P. Fan, “Validated LC/MS/ MS Assay for Curcumin and Tetrahydrocurcumin in Rat Plasma and Application to Pharmacokinetic Study of Phospholipids Complex of Curcumin,” Journal of Phar maceutical and Biomedical Analysis, Vol. 40, No. 3, 2006, pp. 720-727. doi:10.1016/j.jpba.2005.09.032

[21]   S. L. Thomas, D. Zhong, W. Zhou, S. Malik, D. Liotta, J. P. Snyder, E. Hamel, and P. Giannakakou, “EF24, a Novel Curcumin Analog, Disrupts the Microtubule Cytoskeleton and Inhibits HIF-1,” Cell Cycle, Vol. 7, No. 15, 2008, pp. 2409-2417.

[22]   H. Hatcher, R. Planalp, J. Cho, F. M. Torti and S. V. Torti, “Curcumin: From Ancient Medicine to Current Clinical Trials,” Journal Cellular and Molecular Life Sciences, Vol. 65, No. 11, 2008, pp. 1631-1652. doi:10.1007/s00018-008-7452-4

[23]   R. Ravichandran, “Nanoparticles in Drug Delivery: Po tential Green Nanobiomedicine Applications,” International Journal of Green Nanotechnology: Biomedicine, Vol. 1, No. 2, 2009, pp. B108-B130.

[24]   R. Ravichandran, “Nanotechnology-Based Drug Delivery Systems,” NanoBiotechnology, Vol. 5, No. 1, 2010, pp. 17-33. doi:10.1007/s12030-009-9028-2

[25]   X. Chen, T. J. Young, M. Sarkari, R. O. Williams and K. P. Johnston, “Preparation of Cyclosporine a Nanoparticles by Evaporative Precipitation into Aqueous Solution,” International Journal of Pharmaceutics, Vol. 242, No. 1, 2002, pp. 3-14. doi:10.1016/S0378-5173(02)00147-3

[26]   R. H. Muller, C. Jacobs and O. Kayser, “Nanosuspensions as Particulate Drug Formulations in Therapy Ra tionale for Development and What We Can Expect for the Future,” Advanced Drug Delivery Reviews, Vol. 47, No. 1, 2001, pp. 3-19. doi:10.1016/S0169-409X(00)00118-6

[27]   H. G. Weder and P. van Hoogevest, “Nanosuspensions for Intravenous Administration,” US Patent No. 5726164, 1998.

[28]   R. H. Muller and C. Jacobs, “Buparvaquone Mucoadhe sive Nanosuspensions: Preparation, Optimisation and Long Term Stability,” International Journal of Pharmaceutics, Vol. 237, No. 1, 2002, pp. 151-161. doi:10.1016/S0378-5173(02)00040-6

[29]   B. E. Rabinow, “Nanosuspensions in Drug Delivery,” Nature Reviews Drug Discovery, Vol. 3, 2004, pp. 785 796. doi:10.1038/nrd1494

[30]   C. M. Keck and R. H. Muller, “Drug Nanocrystals of Poorly Soluble Drugs Produced by High Pressure Ho mogenization,” European Journal of Pharmaceutics and Biopharmaceutics, Vol. 62, No. 1, 2006, pp. 3-16. doi:10.1016/j.ejpb.2005.05.009

[31]   G. G. Liversidge and K. C. Cundy, “Particle Size Reduc tion for Improvement of Oral Bioavailability of Hydro phobic Drugs: I. Absolute Oral Bioavailability of Nano crystalline Danazol in Beagle Dogs,” International Journal of Pharmaceutics, Vol. 125, No. 1, 1995, pp. 91-97. doi:10.1016/0378-5173(95)00122-Y

[32]   J. Jinno, K. Naoki, M. Miyake, K. Yamada, T. Mukia, M. Odomi, H. Togu-chi, G. G. Liversidge, K. Higaki and T. Kimura, “Effect of Particle Size Reduction on Dissolution and Oral Absorption of a Poorly Water-Soluble Drug, Cilostazol, in Beagle Dogs,” Journal of Controlled Re lease, Vol. 111, No. 1-2, 2006, pp. 56-64. doi:10.1016/j.jconrel.2005.11.013

[33]   G. G. Liversidge and P. Conzentino, “Drug Particle Size Reduction for Decreasing Gastric Irritancy and Enhancing Absorption of Naproxen in Rats,” International Journal of Pharmaceutics, Vol. 125, No. 2, 1995, pp. 309-313. doi:10.1016/0378-5173(95)00148-C

[34]   L. Gao, D. Zhang and M. Chen, “Drug Nanocrystals for the Formulation of Poorly Soluble Drugs and Its Applica tion as a Potential Drug Delivery System,” Journal of Nanoparticle Research, Vol. 10, No. 5, 2008, pp. 845-862. doi:10.1007/s11051-008-9357-4

[35]   R. Ravichandran, “Preparation and Characterisation of Cur cumin Nanosuspension for Enhanced Solubility and Dis solution Velocity,” International Journal of Nano and Bio materials, Vol. 3, No. 2, 2010, pp. 153-186. doi:10.1504/IJNBM.2010.037803

[36]   F. Dons, Y. Wang, J. Li and Q. Huang, “Preparation of Curcumin Sub-Micrometer Dispersions by High-Pressure Homogenization,” Journal of Agricultural and Food Chemistry, Vol. 58, No. 5, 2010, pp. 2848-2853. doi:10.1021/jf903968x

[37]   A. A. Noyes and W. R. Whitney, “The Rate of Solution of Solid Substances in Their Own Solutions,” Journal of the American Chemical Society, Vol. 19, No. 12, 1897, pp. 930-934. doi:10.1021/ja02086a003

[38]   R. H. Muller, C. Jacobs and O. Kayser, “Nanosuspensions for the Formulation of Poorly Soluble Drugs,” In: F. Nielloud and G. Marti-Mestres, Eds., Pharmaceutical Emulsions and Suspensions, Marcel Dekker, New York, 2000, pp. 383-407.

[39]   R. H. Muller and A. Akkar, “Drug Nanocrystals of Poorly Soluble Drugs,” In: H. S. Nalwa, Ed., Encyclopedia of Nanoscience and Nanotechnology, American Scientific Publishers, Stevenson Ranch, 2004, pp. 627-638.

[40]   R. Takano, K. Furumoto, K. Shiraki, N. Takata, Y. Hayashi, Y. Aso and S. Yamashita, “Rate-Limiting Steps of Oral Absorption for Poorly Water-Soluble Drugs in Dogs; Prediction from a Mini Scale Dissolution Test and a Physiologically-Based Computer Simulation,” Pharma ceutical Research, Vol. 25, No. 10, 2008, pp. 2334-2344. doi:10.1007/s11095-008-9637-9

[41]   R. J. Hintz and K. C. Johnson, “The Effect of Particle Size Distribution on Dissolution Rate and Oral Absorp tion,” International Journal of Pharmaceutics, Vol. 51, No. 1, 1989, pp. 9-17. doi:10.1016/0378-5173(89)90069-0

[42]   C. Keck, A. Fichtinger, H. Viernstein and R. H. Muller, “Oral Drug Nanocrystals-Effect of Potential Aggregation on Bioavailability,” Annual Meeting of Pharmaceutical Scientists (AAPS), Baltimore, 2004, p. 2746.